Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61841
Type: Artigo de Periódico
Title: Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)
Authors: Ligia Yukie Sassaki
Marley Ribeiro Feitosa
Carlos Henrique Marques Dos Santos
Manoel Alvaro de Freitas Lins Neto
Abel Botelho Quaresma
Sergio Figueiredo de Lima Junior
Graciana Bandeira Salgado de Vasconcelos
Ornella Sari Cassol
Arlene Dos Santos Pinto
Gustavo Kurachi
Francisco de Assis Goncalves Filho
Daniela Oliveira Magro
Rodrigo Galhardi Gasparini
Thaísa Kowalski Furlan
Wilson Roberto Catapani
Cláudio Saddy Rodrigues Coy
Vivian de Souza Menegassi
Marilia Majeski Colombo
Renata de sá Brito Fróes
Fabio Vieira Teixeira
Antonio Carlos Moraes
Genoile Oliveira Santana
Rogerio Saad-hossne
José Miguel Luz Parente
Eduardo Garcia Vilela
Natália Sousa Freitas Queiroz
Paulo Gustavo Kotze
Julio Pinheiro Baima
Cristina Flores
Lucianna Motta Correia
Lívia Medeiros Soares Celani
Maria de Lourdes de Abreu Ferrari
Patricia Zacharias
Abstract: Background Anti-TNF therapy represented a landmark in medical treatment of ulcerative colitis (UC). There is lack of data on the efficacy and safety of these agents in Brazilian patients. The present study aimed to analyze rates of clinical and endoscopic remission comparatively, between adalimumab (ADA) and infliximab (IFX), in Brazilian patients with UC, and evaluate factors associated with clinical and endoscopic remission after 1 year of treatment. Methods A national retrospective multicenter study (24 centers) was performed including patients with UC treated with anti-TNF therapy. Outcomes as clinical response and remission, endoscopic remission and secondary loss of response were measured in different time points of the follow-up. Baseline predictive factors of clinical and endoscopic remission at week 52 were evaluated using logistic regression model. Indirect comparisons among groups (ADA and IFX) were performed using Student's t, Pearson χ2 or Fisher's exact test when appropriated, and Kaplan Meier analysis. Results Overall, 393 patients were included (ADA, n = 111; IFX, n = 282). The mean age was 41.86 ± 13.60 years, 61.58% were female, most patients had extensive colitis (62.40%) and 19.39% had previous exposure to a biological agent. Overall, clinical remission rate was 66.78%, 71.62% and 82.82% at weeks 8, 26 and 52, respectively. Remission rates were higher in the IFX group at weeks 26 (75.12% vs. 62.65%, p < 0.0001) and 52 (65.24% vs. 51.35%, p < 0.0001) when compared to ADA. According to Kaplan–Meier survival curve loss of response was less frequent in the Infliximab compared to Adalimumab group (p = 0.001). Overall, endoscopic remission was observed in 50% of patients at week 26 and in 65.98% at week 52, with no difference between the groups (p = 0.114). Colectomy was performed in 23 patients (5.99%). Age, non-prior exposure to biological therapy, use of IFX and endoscopic remission at week 26 were associated with clinical remission after 52 weeks. Variables associated with endoscopic remission were non-prior exposure to biological therapy, and clinical and endoscopic remission at week 26. Conclusions IFX was associated with higher rates of clinical remission after 1 year in comparison to ADA. Non-prior exposure to biological therapy and early response to anti-TNF treatment were associated with higher rates of clinical and endoscopic remission.
Subject: Colite Ulcerativa
Adalimumab
Brasil
language: eng
metadata.dc.publisher.country: Brasil
Publisher: Universidade Federal de Minas Gerais
Publisher Initials: UFMG
metadata.dc.publisher.department: MED - DEPARTAMENTO DE CLÍNICA MÉDICA
MEDICINA - FACULDADE DE MEDICINA
Rights: Acesso Aberto
metadata.dc.identifier.doi: https://doi.org/10.1186/s12876-022-02341-7
URI: http://hdl.handle.net/1843/61841
Issue Date: 29-May-2022
metadata.dc.url.externa: https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02341-7
metadata.dc.relation.ispartof: BMC Gastroenterology
Appears in Collections:Artigo de Periódico



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.